On November 29, 2024, Henlius announced that the first commercial shipment of Hercessi" (trastuzumab-strf), a biosimilar of Genentech's Herceptin ® (trastuzumab), had been sent to the U.S. Herceptin ® biosimilars have been available in the U.S. since July 2019, and Hercessi" is the sixth to launch. According to Samsung Bioepis's Q4 2024 Biosimilar Market Dynamics Report, Herceptin ® biosimilars have achieved 86% market share during their time on the market.